Search

everythinglearnresearchcommunity

for

Search:↓

Red light therapy with dual wavelengths (650nm and 850nm) can stimulate hair regrowth without DHT blockers. Consistent use of a panel with these wavelengths has shown positive results in hair regrowth.

Latisse (bimatoprost) is discussed as a potential treatment for hair growth due to difficulty obtaining PGE2. Users also mention concerns about sourcing reliable products from China.

2-deoxy-d-ribose hair serum is now available in Australia, potentially aiding hair loss by promoting new blood vessel growth. Users are discussing its potential effectiveness compared to other treatments like Minoxidil, finasteride, and RU58841.

The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.

KX-826 Phase II results show that a 0.5% concentration performs better than 1% for treating male pattern baldness. Concerns about receptor upregulation from long-term DHT antagonism were mentioned.

Kintor edited their Amazon page, removing claims that KX-826 provides "real" visible results from clinical experiments. The discussion includes treatments like Minoxidil, finasteride, and RU58841.

The conversation discusses hair regrowth progress using topical dutasteride with cetirizine, laser therapy, and growth serum. The user observes miniaturized, vellus hairs on the scalp.

Hair loss treatments, specifically about the effectiveness of RU58841 compared to Pyrilutamide. Molecular weights and side effects were discussed in terms of efficacy and cost-effectiveness.

The conversation discusses GT20029, a drug in Phase II trials that targets androgen receptors with minimal systemic effects, and TDM-105795, a growth stimulant with a different mechanism than minoxidil that may revive papilla stem cells. Both are potential new treatments for hair loss.

PRP treatments have been effective for the user, with a new recommendation of using a high-quality plasma kit once a year. The user seeks experiences with this specific PRP approach.

Hair loss discussion includes Amplifica, a new treatment by Dr. Rassman and Dr. Plikus using molecules from hairy moles. No progress updates mentioned.

The user experienced side effects from RU58841, including dry eyes and potential eyesight issues, and decided to stop using it. They confirmed the product's legitimacy but advised caution due to its experimental status and lack of safety data.

Hair regrowth using estradiol, spironolactone, minoxidil, and finasteride, showing significant improvement over four years. HRT is not advised for cis men solely for hair loss due to feminizing effects.

ET-02 is seen as promising for addressing hair loss and graying, but PP405 is more advanced in development and has better publicity. Some users plan to use both treatments alongside minoxidil and dutasteride.

RU-58642 is a powerful anti-androgen that was not developed further, possibly due to safety concerns or financial reasons. RU58841 is a topical alternative, but it is less effective than finasteride and dutasteride, and its long-term effects are not well-studied.

Pyrilutamide, a potential topical treatment for male pattern baldness, and the user's anticipation of its Phase 2 trial results. Several users discussed their experiences with Finasteride and RU58841, while others voiced skepticism about the efficacy of Pyrilutamide.

Scientists discovered a sugar gel, 2dDR-SA, that increased hair growth in mice. Users discussed its potential, comparing it to other treatments like Minoxidil and finasteride.

RU58841 not working for hair loss after 10 months. Concerns about purity of experimental drugs.

The conversation discusses the potential of a new hair loss treatment, GT20029, which targets androgen receptors in the scalp and is in phase 1 trials in China. Users express hope that this treatment will be more effective than current options like Minoxidil and Finasteride.

The conversation is about the use and application of CB-03-01-2 (Breezula) for hair loss, including questions about its form, how to apply it, and the duration 10g would last. Specific treatments discussed are Minoxidil, finasteride, and RU58841.

Pelage plans to release phase 2 results and start phase 3 trials for PP405 in 2050, but skepticism remains due to past delays and unfulfilled promises. Users express frustration over the lack of progress in hair loss treatments, mentioning Minoxidil, finasteride, RU58841, CB-03-01, and Fluridil.

A user warns against buying the Koreabeautics V2 microneedling pen, claiming it's marketed through fake success stories and is overpriced. Another user shares their experience, acknowledging the pen's quality but agreeing it's too expensive and reliant on frequent needle head replacements.

PTD-DBM therapy for hair loss is being developed by Dr. Kang-Yell Choi, with human testing planned in South Korea. Some clinics in the U.S. offer PTD-DBM/valproic acid therapy, but it hasn't completed trials yet.

Low-level laser therapy (LLLT) stimulates hair growth but current devices are expensive. A proposed non-profit project aims to create affordable, 3D-printed LLLT devices and collect data on their effectiveness.

The user is using RU58841, Revivogen, Regenepure ketoconazole shampoo, and plans to use a stimufield cap to address hair loss. They aim to avoid finasteride and minoxidil while hoping to stop hair loss and regrow hair.

Winlevi (clascoterone), a DHT blocker, is being considered for hair loss treatment, though it's primarily an acne medication. Users discuss its potential effectiveness and note it may only work for a short time.

The conversation is about the anticipated results of Pelage's Phase 2a clinical trial for their topical hair loss treatment, PP405. Users speculate on when the results will be available, noting that delays might indicate less successful outcomes.

KX-826 (Pyrilutamide) 0.5% and 1.0% solutions showed promising results in increasing hair count for male androgenetic alopecia, with the 0.5% dose slightly outperforming the 1% dose. The treatment was well-tolerated with no sexual side effects, but skepticism remains due to past inconsistencies in trial results.

A user discovered CosmeRNA, a new hair loss treatment with clinical research backing, set to release soon. The conversation revolves around its potential effectiveness, cost, and how it compares to existing treatments like Minoxidil and Finasteride, with some users expressing hope for a side-effect-free option.

The conversation discusses using topical synthetic prostaglandins like Bimatoprost, Latanoprost, and cetirizine for hair growth. The user shares a link suggesting these treatments may be effective.